


TEAM EXPERIENCE - ONCOLOGY & BIOSIMILARS

Late Phase 41%



Early Phase 59%


REGULATORY SUBMISSIONS - BIOSIMILARS



Other Regulatory Includes	Studies
CANADA	1
CDSCO	1
DCGI+ROW	1
US & EU	1
USFDA/EU/Emerging Market	1

REGULATORY SUBMISSIONS - ONCOLOGY

Other Regulatory Includes	Studies
EMA	2
MENA	2
TGA	2
ANVISA	1
DCGI+ROW	1
EMA/Malaysia	1
EU/Turkey	1
NMPA	1
USFDA+EU	1



TEAM EXPERIENCE - ONCOLOGY & BIOSIMILARS

Early Phase - Biosimilars

Molecule	# of Studies
Adalimumab 40 mg SC InJection	1
Darbepoetin Alfa 0.75 µg/kg SC/ IV Injection	1
Darbepoetin Alfa 60/40µg SC/ IV Injection	1
enoxaparin Na 100 mg/ml SC InJection	4
Pegfilgrastim 6 mg SC InJection	1
Repoitin Injection 10000IU/mL IV-Injection	1
Repoitin Injection 10000IU/mL SC-Injection	1
Trastuzumab 150 mg Powder IV	1
Bevacizumab 100 mg (25 mg/mL) IV infusion	1
Etanercept 50 mg Injection	1
	13

Early Phase - Oncology

Molecule	Strength	# of Studies
Alectinib	150 mg	2
Cabozantinib	40 mg	2
	60 mg	3
Dasatinib	20 mg	1
	50 mg	3
	100 mg	22
	140 mg	2
Dasatinib	140 mg	1
Erlotinib	150 mg	19
Erlotinib (Redose)	150 mg	1
Ibrutinib	20 mg	1
	140 mg	16
	560 mg	11
Imatinib	400 mg	4
Nilotinib	200 mg	4
Nintedanib	150 mg	8
Osimertinib	80 mg	4
Pazopanib	200 mg	9
	400 mg	1
Ruxolitinib	50 mg	2
Sorafenib	200 mg	2
Sunitinib	50 mg	1
Tofacitinib	5 mg	4
	10 mg	3
	11 mg	19
	22 mg	7
Zanubrutinib	80 mg	2

Late Phase - Biosimilars

Therapeutic Area	Molecule	Indication	Regulatory	Sites	Patients
Gynaecology	Recombinant Human FSH	IVF	DCGI	9	116
Oncology	Rituximab Biosimilar	Diffuse large B-cell lymphoma	EU	13	73
	Bevacizumab	Metastatic colorectal cancer	EU	6	24
			DCGI	26	111
		Non-small-cell lung carcinoma	USFDA	30	650
	Trastuzumab NCE	Metastatic Breast Cancer	DCGI + ROW	34	102
NA	10		10		
Ophthalmology	Aflibercept	Diabetic Macular Edema	USFDA + EU + Japan + India	15	100
			USFDA + EU + Japan + India	15	65

Late Phase - Oncology

Molecule	Indication	Regulatory	Sites	Patients
Bevacizumab	Metastatic colorectal cancer	EU	6	24
		DCGI	26	111
	Non-small-cell lung carcinoma	USFDA	30	650
NCE		USFDA	10	60
Capecitabine	Metastatic breast/Colorectal cancer	USFDA	14	54
		USFDA+EU	10	42
		EU	10	46
Imatinib	GIST and CML	USFDA	6	38
Lenvatinib	Thyroid Cancer	DCGI	10	50
Olaparib	Ovarian Cancer Cancer and Stable on Olaparib Therapy	USFDA	12	48
		USFDA	12	28
Paclitaxel	Metastatic Breast Cancer	USFDA	21	90
		USFDA	5	50
		USFDA	5	20
		USFDA	10	90
		NA	10	20
Rituximab	Diffuse large B-cell lymphoma	EU	13	73
Sunitinib	Renal Cell Carcinoma	USFDA	5	13
		USFDA	12	46
Transtuzumab	Early Breast Cancer Metastatic Breast Cancer	USFDA	34	102
		NA		
		DCGI+ROW		